Melissa S Dillmon1, Erin B Kennedy2, Mary K Anderson3, Michael Brodersen4, Howard Cohen5, Steven L D Amato6, Patty Davis7, Gury Doshi8, Stuart Genschaw9, Issam Makhoul10, Wayne Ormsby11, Rajiv Panikkar12, Eileen Peng13, Luis E Raez14, Ellen A Ronnen13, Bill Wimbiscus15, Michael Reff15. 1. Harbin Clinic, Rome, GA. 2. American Society of Clinical Oncology, Alexandria, VA. 3. Norton Cancer Institute, Louisville, KY. 4. Nebraska Cancer Specialists, Omaha, NE. 5. Yale New Haven Health, New Haven, CT. 6. New England Cancer Specialists, Portland, ME. 7. Oncology Hematology Associates, Springfield, MO. 8. Texas Oncology, Houston, TX. 9. Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI. 10. University of Arkansas for Medical Sciences, Little Rock, AK. 11. Utah Cancer Specialists, Salt Lake City, UT. 12. Geisinger Cancer Institute, Danville, PA. 13. Regional Cancer Care Associates, East Brunswick, NJ. 14. Memorial Healthcare System/Florida International University, Pembroke Pines, FL. 15. National Community Oncology Dispensing Association, Cazenovia, NY.
Abstract
PURPOSE: To provide standards for medically integrated dispensing of oral anticancer drugs and supportive care medications. METHODS: An Expert Panel was formed, and a systematic review of the literature on patient-centered best practices for the delivery of oral anticancer and supportive care drugs was performed to April 2019 using PubMed and Google Scholar. Available patient-centered standards, including one previously developed by the National Community Oncology Dispensing Association (NCODA), were considered for endorsement. Public comments were solicited and considered in preparation of the final manuscript. RESULTS: A high-quality systematic review that was current to May 2016 was adopted into the evidence base. Five additional primary studies of multifaceted interventions met the inclusion criteria. These studies generally included a multicomponent intervention, often led by an oncology pharmacist, and also included patient education and regular follow-up and monitoring. These interventions resulted in significant improvements to patient quality and safety and demonstrated improvements in adherence and other patient outcomes. CONCLUSION: The findings of the systematic review were consistent with the NCODA patient-centered standards for patient relationships and education, adherence, safety, collection of data, documentation, and other areas. NCODA standards were adopted and used as basis for these American Society of Clinical Oncology/NCODA standards. Additional information is available at www.asco.org/mid-standards.
PURPOSE: To provide standards for medically integrated dispensing of oral anticancer drugs and supportive care medications. METHODS: An Expert Panel was formed, and a systematic review of the literature on patient-centered best practices for the delivery of oral anticancer and supportive care drugs was performed to April 2019 using PubMed and Google Scholar. Available patient-centered standards, including one previously developed by the National Community Oncology Dispensing Association (NCODA), were considered for endorsement. Public comments were solicited and considered in preparation of the final manuscript. RESULTS: A high-quality systematic review that was current to May 2016 was adopted into the evidence base. Five additional primary studies of multifaceted interventions met the inclusion criteria. These studies generally included a multicomponent intervention, often led by an oncology pharmacist, and also included patient education and regular follow-up and monitoring. These interventions resulted in significant improvements to patient quality and safety and demonstrated improvements in adherence and other patient outcomes. CONCLUSION: The findings of the systematic review were consistent with the NCODA patient-centered standards for patient relationships and education, adherence, safety, collection of data, documentation, and other areas. NCODA standards were adopted and used as basis for these American Society of Clinical Oncology/NCODA standards. Additional information is available at www.asco.org/mid-standards.
Authors: Giselle K Perez; John M Salsman; Kaitlyn Fladeboe; Anne C Kirchhoff; Elyse R Park; Abby R Rosenberg Journal: Am Soc Clin Oncol Educ Book Date: 2020-03
Authors: Sarah M Belcher; Emily Mackler; Benyam Muluneh; Pamela K Ginex; Mary K Anderson; Elizabeth Bettencourt; Ryan K DasGupta; Jennifer Elliott; Erica Hall; Michelle Karlin; Diana Kostoff; Victoria K Marshall; Vanessa E Millisor; Maegan Molnar; Susan M Schneider; Janelle Tipton; Susan Yackzan; Kristine B LeFebvre; Kapeena Sivakumaran; Haya Waseem; Rebecca L Morgan Journal: Oncol Nurs Forum Date: 2022-06-17 Impact factor: 1.803